Degraded coral reefs are far quieter than five years ago, and no longer sound like suitable habitat to young fish searching for a place to live and breed, according to research co-authored by the University of Bristol and published today in Proceedings of the National Academy of Sciences USA.
Villagers from a remote part of Mozambique have said that a borehole part-funded by generous Bristolians has “changed everything for our village”.
Groundbreaking new technology is set to revolutionise match day and how fans experience sport following successful trials at a major stadium. The innovation, the first of its kind in the UK, could transform traditional sports venues into fully smart-enabled stadiums, offering fans unprecedented levels of interaction and connectivity.
An innovative project which offers a testbed for developing and trialling AI solutions has won a prestigious national award, further cementing the University of Bristol’s reputation as an AI trailblazer.
A University of Bristol professor who is playing a pivotal role in advance telecommunications technology research has been named in the 2025 Photonics 100 list which recognises individuals driving innovation in the field of photonic science.
The University of Bristol is set to play a major role in a series of new hubs being launched to ensure the UK fully benefits from the potential of quantum technologies in areas ranging from healthcare to national security.
.jpg)
Professor Dimitra Simeonidou, Director of the Smart Internet Lab at the University of Bristol, will take a leading role at the upcoming Optical Fiber Communications (OFC) Conference and Exhibition being held in San Diego, California.
Representatives from the University of Bristol will be playing a prominent role at the Mobile World Congress (MWC) being held in Barcelona from 26-29 February.
The risk of blood clots after COVID-19 vaccinations is very low finds a new study of 46-million adults in England. The research, which involved University of Bristol academics, showed that people vaccinated with Oxford-AstraZeneca or Pfizer-BioNTech had a lower risk of all venous clots (such as deep vein thrombosis and pulmonary embolism) and all arterial clots (such as strokes and heart attacks), particularly in people over 70 years.
The publication of a major new survey of Irish history will be celebrated at Dublin Castle today (Monday, April 30).
